Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook
Alignment Healthcare, Inc. (ALHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook Reports third-quarter revenue of $ 1.36 billion, representing 36.7% year-over-year growth Grows health plan membership 31.2% year-over-year to 301,200 members Issues fourth-quarter gui
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
the lowered profit guidance may trigger a short‑term sell‑off, but strong membership growth offers a longer‑term upside narrative.
Market read
the earnings release provides fresh guidance that can move the stock and influences peers in the Medicare Advantage space.
What to watch
the 31% membership increase could drive longer‑term revenue upside despite short‑term profit compression
Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook
Revenue and membership grew 36.7% and 31.2% year-over-year, respectively, but higher medical costs drove a 32.8% decline in adjusted EBITDA, a net loss of $8.1 million, and lower full-year adjusted gross profit and adjusted EBITDA guidance.
Actuals vs. the company’s prior outlook
from its previous release| Metric | Guided | Reported | Verdict |
|---|---|---|---|
| Revenue, Q3 | $1,300 to $1,320 | $ 1,358,290 (in thousands) | above |
| Adjusted gross profit, Q3 | $148 to $158 | $ 142,205 (in thousands) | below |
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Health plan membership at end of quarterother | approximately 301,200 | – | up 31.2% year-over-year |
| Total revenues, three months ended September 30, 2026GAAP | $1.36B | – | up 36.7% year-over-year |
| Earned premiums, three months ended September 30, 2026GAAP | $1.35B | – | – |
| Other revenue, three months ended September 30, 2026GAAP | $10.03M | – | – |
| Medical expenses, three months ended September 30, 2026GAAP | $1.22B | – | – |
| Medical benefits ratio, three months ended September 30, 2026non-GAAP | 89.5% | – | an increase of approximately 240 basis points year-over-year |
| Selling, general, and administrative expenses, three months ended September 30, 2026GAAP | $136.4M | – | – |
| Depreciation and amortization, three months ended September 30, 2026GAAP | $8.11M | – | – |
| Total expenses, three months ended September 30, 2026GAAP | $1.36B | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$3.79M | – | – |
| Adjusted gross profit, three months ended September 30, 2026non-GAAP | $142.2M | – | up 11.6% year-over-year |
| Interest expense, three months ended September 30, 2026GAAP | $4.28M | – | – |
| Income (loss) before income taxes, three months ended September 30, 2026GAAP | −$8.07M | – | – |
| Provision (benefit) for income taxes, three months ended September 30, 2026GAAP | −$22K | – | – |
| Net income (loss), three months ended September 30, 2026GAAP | −$8.05M | – | – |
| Net income (loss) attributable to Alignment Healthcare, Inc., three months ended September 30, 2026GAAP | −$8.05M | – | – |
| Basic net income (loss) per share attributable to Alignment Healthcare, Inc., three months ended September 30, 2026GAAP | (0.04) | – | – |
| Diluted net income (loss) per share attributable to Alignment Healthcare, Inc., three months ended September 30, 2026GAAP | (0.04) | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $21.81M | – | declined 32.8% year-over-year |
| Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP | 1.6% | – | – |
| Total revenues, nine months ended September 30, 2026GAAP | $3.93B | – | – |
| Earned premiums, nine months ended September 30, 2026GAAP | $3.90B | – | – |
| Other revenue, nine months ended September 30, 2026GAAP | $27.67M | – | – |
| Medical expenses, nine months ended September 30, 2026GAAP | $3.46B | – | – |
| Selling, general, and administrative expenses, nine months ended September 30, 2026GAAP | $388.5M | – | – |
| Depreciation and amortization, nine months ended September 30, 2026GAAP | $23.80M | – | – |
| Total expenses, nine months ended September 30, 2026GAAP | $3.88B | – | – |
| Income from operations, nine months ended September 30, 2026GAAP | $53.81M | – | – |
| Adjusted gross profit, nine months ended September 30, 2026non-GAAP | $471.0M | – | – |
| Net income, nine months ended September 30, 2026GAAP | $39.92M | – | – |
| Net income attributable to Alignment Healthcare, Inc., nine months ended September 30, 2026GAAP | $39.92M | – | – |
| Basic net income per share attributable to Alignment Healthcare, Inc., nine months ended September 30, 2026GAAP | 0.19 | – | – |
| Diluted net income per share attributable to Alignment Healthcare, Inc., nine months ended September 30, 2026GAAP | 0.19 | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | $127.8M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Three Months Ending December 31, 2026 and Twelve Months Ending December 31, 2026 outlook
- Revenue$1,316 for three months ending December 31, 2026; $5,245 for twelve months ending December 31, 2026
- NoteHealth Plan Membership: no less than 305,000 for three months ending December 31, 2026; no less than 305,000 for twelve months ending December 31, 2026
- NoteAdjusted Gross Profit: $104 for three months ending December 31, 2026; $575 for twelve months ending December 31, 2026
- NoteAdjusted EBITDA: $(28) for three months ending December 31, 2026; $100 for twelve months ending December 31, 2026
What drove it
- Health plan membership was approximately 301,200, up 31.2% year-over-year.
- Total revenue was $1,358.3 million, up 36.7% year-over-year.
- Full-year health plan membership and revenue guidance was raised to reflect continued sales momentum.
- Medical benefits ratio reflected previously expected changes in Part D seasonality and timing of clinical investments.
Concerns
- Medical trends ran higher than expected.
- The medical benefits ratio was 89.5%, an increase of approximately 240 basis points year-over-year.
- The company cited higher costs from elevated appeals and disputes and increased costs within catastrophic cases and skilled nursing categories.
- Full-year adjusted gross profit and adjusted EBITDA guidance was lowered to reflect higher medical costs experienced during the third quarter.
- The third quarter recorded a loss from operations of $3.8 million and net loss of $8.1 million.
What to watch
- Execution against actions underway, which revised guidance does not assume will provide any benefit.
- Fourth-quarter medical-cost trends, including appeals and disputes, catastrophic cases, and skilled nursing categories.
- Health plan membership against guidance of no less than 305,000.
- Fourth-quarter adjusted gross profit guidance of $104 and adjusted EBITDA guidance of $(28).
- Full-year adjusted gross profit guidance of $575 and adjusted EBITDA guidance of $100.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $ 727,694; December 31, 2025: $ 575,817
- Investments - current as of September 30, 2026: 15,260; December 31, 2025: 28,413
- Total assets as of September 30, 2026: $ 1,296,863; December 31, 2025: $ 1,065,786
- Medical expenses payable as of September 30, 2026: $ 621,746; December 31, 2025: $ 474,569
- Long-term debt, net of debt issuance costs, as of September 30, 2026: 324,497; December 31, 2025: 323,176
- Total liabilities as of September 30, 2026: 1,019,751; December 31, 2025: 886,509
- Total stockholders' equity as of September 30, 2026: 277,112; December 31, 2025: 179,277
- Net cash provided by operating activities, nine months ended September 30, 2026: 158,395; 2025: 190,302
- Acquisition of property and equipment, nine months ended September 30, 2026: (25,952); 2025: (21,752)
- Net cash used in investing activities, nine months ended September 30, 2026: (12,327); 2025: (7,811)
- Net cash provided by financing activities, nine months ended September 30, 2026: 5,834; 2025: 2,745
- Net increase in cash, nine months ended September 30, 2026: 151,902; 2025: 185,236
- Cash, cash equivalents and restricted cash at end of period, September 30, 2026: $ 729,839; September 30, 2025: $ 620,178
Analysis
Alignment reported third-quarter total revenue of $1,358.3 million, up 36.7% year-over-year, while health plan membership reached approximately 301,200, up 31.2% year-over-year. The company characterized the membership and revenue results as evidence of continued demand, and raised full-year health plan membership and revenue guidance to reflect continued sales momentum.
Profitability lagged the top-line expansion. Adjusted gross profit increased 11.6% year-over-year to $142.2 million, while the medical benefits ratio was 89.5%, an increase of approximately 240 basis points year-over-year. Management attributed the result to expected Part D seasonality and clinical-investment timing, alongside higher costs from elevated appeals and disputes and increased catastrophic-case and skilled-nursing costs.
The cost pressure moved quarterly GAAP results into loss territory. Loss from operations was $3.8 million compared with income from operations of $7.7 million in the prior-year quarter, and net loss was $8.1 million compared with net income of $3.7 million. Adjusted EBITDA declined 32.8% year-over-year to $21.8 million, with an adjusted EBITDA margin of 1.6%.
The balance sheet showed $727.7 million of cash and cash equivalents and $324.5 million of long-term debt, net of debt issuance costs, at September 30, 2026. Net cash provided by operating activities for the nine months ended September 30, 2026 was $158.4 million, compared with $190.3 million in the prior-year period. The release reported no capital-return activity.
For the fourth quarter, the company guided to revenue of $1,316, adjusted gross profit of $104, and adjusted EBITDA of $(28). Full-year guidance calls for revenue of $5,245, adjusted gross profit of $575, and adjusted EBITDA of $100, with health plan membership of no less than 305,000. The company lowered its adjusted gross profit and adjusted EBITDA outlook based on third-quarter medical costs and stated that revised guidance assumes no benefit from actions underway.
Management, verbatim
Our third-quarter membership and revenue growth demonstrate continued demand for Alignment’s products and services, while medical trends ran higher than expected.
John Kao, chairman and CEO
We are taking a prudent approach to the fourth quarter and lowering our outlook based on current headwinds.
John Kao, chairman and CEO
Our revised guidance does not assume any benefit from the actions underway.
John Kao, chairman and CEO
Not in the filing
stated, not guessed- GAAP gross margin was not reported.
- Prior-quarter comparisons were not reported for the disclosed operating metrics.
- No reportable revenue segments or segment-level results were provided.
- Free cash flow was not reported.
- Share repurchases, dividends, and other capital-return activity were not reported.
- Fourth-quarter and full-year guidance for operating expenses and tax rate was not reported.
- GAAP EPS guidance was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Alignment Healthcare filed a Form 8‑K reporting Q3 2026 results and updating its FY outlook.
Ticker impact
the company lowered guidance for adjusted gross profit and adjusted EBITDA for FY 2026
likely downside pressure as investors price in weaker profitability
the 8‑K shows a 32.8% YoY decline in adjusted EBITDA and a cut to profit guidance, which typically triggers sell‑side sentiment
Market effects
signals potential margin pressure for other Medicare Advantage providers
U.S. health‑care sector may see modest pullback
limited to U.S. health‑care equities
Counterpoint
if the membership growth continues, the profit dip could be temporary and the stock may rebound
Key entities
- companyAlignment Healthcare, Inc.
NASDAQ‑listed senior‑care provider




